Price Alert

Precigen Inc. (PGEN)

NASDAQ: PGEN · Real-Time Price · USD

4.56

-0.19 (-4.00%)

At close: Sep 04, 2025, 3:59 PM

4.57

0.22%

Pre-market: Sep 05, 2025, 06:11 AM EDT

-4.00% (1D)

Bid	4.55
Market Cap	1.36B
Revenue (ttm)	4.34M
Net Income (ttm)	-124.5M
EPS (ttm)	-0.41
PE Ratio (ttm)	-11.12
Forward PE	-52.78
Analyst	Buy

Ask	4.79
Volume	5,933,594
Avg. Volume (20D)	7,517,777
Open	4.74
Previous Close	4.75
Day's Range	4.49 - 4.76
52-Week Range	0.65 - 5.23
Beta	1.87

About PGEN

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol PGEN

Website n/a

Full Company Profile

Analyst Forecast

According to 0 analyst ratings, the average rating for PGEN stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

Stock Forecasts

Next Earnings Release

Precigen Inc. is scheduled to release its earnings on Nov 13, 2025, during market hours.
Analysts project revenue of ... Unlock content with Pro Subscription

Why Price Moved

2 weeks ago

+9.15%

Precigen shares are trading higher after JMP Secur... Unlock content with Pro Subscription

3 weeks ago

+58.92%

Precigen shares are trading higher after the company announced the FDA has approved PAPZIMEOS. HC Wainwright & Co. raised its price target on the stock from 6 to $8.5.

News

3 days ago · seekingalpha.com

Precigen, Inc. - Special Call

Precigen, Inc. - Special Call Company Participants Helen Sabzevari - President, CEO & Director Phil Tennant - Chief Commercial Officer Conference Call Participants Swayampakula Ramakanth - H.C. Wainwr...

1 week ago · zacks.com

PGEN Stock Surges 144% in August on FDA Nod for Rare Lung Disease Drug

Precigen stock soars 144% in August after FDA approval of Papzimeos, the first treatment for adults with recurrent respiratory papillomatosis.

2 weeks ago · seekingalpha.com

Undercovered Dozen: Precigen, ONEOK, Bitmine And More

This week's Undercovered Dozen highlights 12 lesser-known stocks and ETFs with compelling investment theses and recent catalysts. Standouts include CGDV's market-beating performance, DIVO's retirement...

2 weeks ago · https://thefly.com

Precigen price target raised to $8 from $6 at Citizens JMP

Citizens JMP raised the firm's price target on Precigen to $8 from $6 and keeps an Outperform rating on the shares. Precigen discussed the approval of PAPZIMEOS for the treatment of respiratory papill...

3 weeks ago · seekingalpha.com

Precigen: This Billion-Dollar Approval Is Still Undervalued

PAPZIMEOS's full FDA approval for RRP is a decisive, de-risking event and validates Precigen's immunotherapy platform. PAPZIMEOS targets a significant unmet need, with potential for $1B+ peak sales, t...

3 weeks ago · benzinga.com

Why Is Precigen Stock Surging On Friday?

On Friday, the U.S. Food and Drug Administration (FDA) approved Precigen Inc.'s PGEN Papzimeos (zopapogene imadenovec-drba) for adult patients with recurrent respiratory papillomatosis (RRP).

3 weeks ago · reuters.com

US FDA approves Precigen's immunotherapy for rare respiratory disease

The U.S. Food and Drug Administration has approved Precigen's immunotherapy to treat adults with a rare respiratory disease, making it the first treatment for the condition to receive the health regul...

2 months ago · seekingalpha.com

Precigen: August Is Pivotal For This Biotech Innovator

Precigen's future hinges on the FDA's approval of PRGN-2012, with a pivotal decision expected August 27, 2025. PRGN-2012 shows strong efficacy and safety, potentially transforming the treatment of Rec...